Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19494554 | 0.87 | ADRA2C (0.32) | ADRA2CKMT2AMEN1PABPC1 | |
| SCHEMBL361227 | 0.77 | ADRA2C (0.39) | ADRA2CKMT2AMEN1PABPC1MAPK1 | |
| SCHEMBL5827548 | 0.67 | ADRA2C (0.31) | ADRA2C | |
| SCHEMBL15215616 | 0.67 | ADRA2C (0.33) | ADRA2C | |
| SCHEMBL13391600 | 0.62 | ADRA2C (0.42) | ADRA2CKMT2AMEN1PABPC1MAPK1 | |
| SCHEMBL8826943 | 0.62 | ADRA2C (0.42) | ADRA2CKMT2AMEN1PABPC1MAPK1 | |
| SCHEMBL11918894 | 0.61 | ADRA2C (0.41) | ADRA2CKMT2AMEN1PABPC1MAPK1 | |
| SCHEMBL162704 | 0.61 | ADRA2C (0.41) | ADRA2CKMT2AMEN1PABPC1MAPK1 | |
| SCHEMBL14986940 | 0.60 | ADRA2C (0.40) | ADRA2CKMT2AMEN1PABPC1MAPK1 | |
| SCHEMBL9665549 | 0.60 | ADRA2C (0.47) | ADRA2CKMT2AMEN1PABPC1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2958926-B1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | VASTHERA CO LTD (KR) | 2023-03-08 | — | — | EP | disclosed |
| US-10450327-B2 | Epidithiodioxopiperazine compound or its derivatives, and the use thereof | VASTHERA CO. LTD. (KR) | 2019-10-22 | — | — | US | disclosed |
| US-20180305377-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2018-10-25 | — | — | US | disclosed |
| EP-3354655-A1 | COMPOSITIONS AND METHODS FOR INHIBITING ACTIVITY OF HYPOXIA-INDUCIBLE TRANSCRIPTION FACTOR COMPLEX AND ITS USE FOR TREATMENT OF TUMORS | University Of Southern California, USC Stevens (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-2890382-B1 | COMPOSITIONS AND METHODS FOR INHIBITING ACTIVITY OF HYPOXIA-INDUCIBLE TRANSCRIPTION FACTOR COMPLEX AND ITS USE FOR TREATMENT OF TUMORS | UNIV SOUTHERN CALIFORNIA (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2890382-B1 | COMPOSITIONS AND METHODS FOR INHIBITING ACTIVITY OF HYPOXIA-INDUCIBLE TRANSCRIPTION FACTOR COMPLEX AND ITS USE FOR TREATMENT OF TUMORS | UNIV SOUTHERN CALIFORNIA (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9765090-B2 | Epidithiodioxopiperazine compound or its derivatives, and the use thereof | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2017-09-19 | — | — | US | disclosed |
| US-9765090-B2 | Epidithiodioxopiperazine compound or its derivatives, and the use thereof | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2017-09-19 | — | — | US | disclosed |
| US-9765090-B2 | Epidithiodioxopiperazine compound or its derivatives, and the use thereof | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2017-09-19 | — | — | US | disclosed |
| US-20170239261-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | VASTHERA CO. LTD. (KR) | 2017-08-24 | — | — | US | disclosed |
| EP-2958926-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | Ewha University-Industry Collaboration Foundation (KR) | 2015-12-30 | — | — | EP | disclosed |
| US-20150284349-A1 | EPIDITHIODIKETOPIPERAZINE COMPOUNDS, COMPOSITIONS, AND METHODS | GLOBAVIR BIOSCIENCES, INC. | 2015-10-08 | — | — | US | disclosed |
| US-20150284349-A1 | EPIDITHIODIKETOPIPERAZINE COMPOUNDS, COMPOSITIONS, AND METHODS | GLOBAVIR BIOSCIENCES, INC. | 2015-10-08 | — | — | US | disclosed |
| US-20150284349-A1 | EPIDITHIODIKETOPIPERAZINE COMPOUNDS, COMPOSITIONS, AND METHODS | GLOBAVIR BIOSCIENCES, INC. | 2015-10-08 | — | — | US | disclosed |
| US-20150246933-A1 | Compositions and Methods for Inhibiting Activity of Hypoxia-Inducible Transcription Factor Complex and Its Use for Treatment of Tumors | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2015-09-03 | — | — | US | disclosed |
| US-20150246933-A1 | Compositions and Methods for Inhibiting Activity of Hypoxia-Inducible Transcription Factor Complex and Its Use for Treatment of Tumors | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2015-09-03 | — | — | US | disclosed |
| US-20150246933-A1 | Compositions and Methods for Inhibiting Activity of Hypoxia-Inducible Transcription Factor Complex and Its Use for Treatment of Tumors | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2015-09-03 | — | — | US | disclosed |
| WO-2015095821-A1 | EPIDITHIODIKETOPIPERAZINE COMPOUNDS, COMPOSITIONS, AND METHODS | GLOBAVIR BIOSCIENCES, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2014035484-A1 | COMPOSITIONS AND METHODS FOR INHIBITING ACTIVITY OF HYPOXIA-INDUCIBLE TRANSCRIPTION FACTOR COMPLEX AND ITS USE FOR TREATMENT OF TUMORS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2014-03-06 | — | — | WO | disclosed |
| WO-2013077709-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESTENOSIS COMPRISING EPIDITHIODIOXOPIPERAZINE COMPOUNDS OR DERIVATIVES THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | 이화여자대학교 산학협력단 (KR) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239261-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | PRDX1, PRDX2, PRDX5 | ADRA2C 109/4885KMT2A 3525/4885MEN1 3479/4885 |
| US-20150246933-A1 | Compositions and Methods for Inhibiting Activity of Hypoxia-Inducible Transcription Factor Complex and Its Use for Treatment of Tumors | HIF1AN, HIF1A, EGLN2 | ADRA2C 2909/4885KMT2A 882/4885MEN1 4533/4885 |
| US-20150284349-A1 | EPIDITHIODIKETOPIPERAZINE COMPOUNDS, COMPOSITIONS, AND METHODS | EGLN3, HIF1AN, EGLN2 | ADRA2C 1425/4885KMT2A 874/4885MEN1 4372/4885 |
| US-10450327-B2 | Epidithiodioxopiperazine compound or its derivatives, and the use thereof | PRDX1, PRDX2, PRDX5 | ADRA2C 109/4885KMT2A 3525/4885MEN1 3479/4885 |
| US-20180305377-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | PRDX1, PRDX2, PRDX5 | ADRA2C 109/4885KMT2A 3525/4885MEN1 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.